AI Article Synopsis
- Rett syndrome (RTT) is a progressive neurological disorder that often leads to epilepsy in 50-90% of patients, some of whom experience hard-to-treat seizures.
- A study was conducted to evaluate the effectiveness of levetiracetam (LEV) in reducing seizure frequency among drug-resistant RTT patients over 6 months, following an 8-week baseline period.
- Results showed a significant decrease in monthly seizure frequency from 21.3 before treatment to 1.5 after 6 months of LEV, indicating the drug's effectiveness and improved quality of life for patients.
Article Abstract
Rett syndrome (RTT) is a progressive neurological disorder characterized by a wide spectrum of phenotypes. Epilepsy is reported to occur in 50-90% of patients with RTT; some develop medically refractory epilepsy. The aim of this study is to investigate the efficacy of levetiracetam (LEV) in drug-resistant patients with RTT. This prospective, pragmatic, open-label study consisted of an 8-week baseline period and a 6-month evaluation period. Efficacy variable was the mean frequency of monthly seizures before, and after 3 and 6 months of treatment with LEV. Eight female patients, aged 7.5-19 years (M12.8+/-5) entered the study. Mean age at epilepsy onset was 25.8+/-14.1 months. All patients showed MeCP2 mutation. Patients had been treated with a mean of 3.4 AEDs (2-7) before LEV. The mean LEV dose was 44.84+/-18.02mg/kg/day. The mean monthly seizure frequency for all types of seizures during the baseline period was 21.3+/-8.1 (range 10-35); after 3 months it was 3.3+/-4.1 (range 0-9) and after 6 months of LEV treatment it was 1.5+/-2 (range 0-4), p<0.0001. The mean follow-up period was 20.2+/-13 months. Mild sleepiness occurred in two patients, one reported intermittent agitation. Levetiracetam appeared effective in our series of drug-resistant RTT patients. All reported a reduction in seizure frequency and consequently a better quality of life.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eplepsyres.2009.10.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The fruit fly as a screening model for antiseizure medications.
Front Pharmacol
December 2024
Department of Epileptology and Neurology, RWTH Aachen University, Aachen, Germany.
Objective: Resistance to antiseizure medications (ASMs) is a major challenge in the treatment of patients with epilepsy. Despite numerous newly marketed ASMs, the proportion of drug-resistant people with epilepsy has not significantly decreased over the years. Therefore, novel and innovative seizure models for preclinical drug screening are highly desirable.
View Article and Find Full Text PDFEfficacy of piracetam in children with breath-holding spells: a systematic review and meta-analysis.
Eur J Pediatr
December 2024
Pediatric Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, 249203, India.
A number of randomized-controlled trials (RCTs) have been conducted comparing the efficacy of piracetam with placebo and other medications in children with breath-holding spells (BHS). However, no systematic review has yet collated all this evidence. All RCTs comparing the efficacy and/or safety of piracetam with placebo or other medications in children with BHS were included.
View Article and Find Full Text PDFThe Antiepileptic Drug Levetiracetam Inhibits Carbonic Anhydrase: and Studies on Catalytically Active Human Isoforms.
ACS Med Chem Lett
December 2024
NEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, University of Florence, Sesto Fiorentino, 50019 Florence Italy.
Several antiepileptic drugs (AEDs) have been found to inhibit human carbonic anhydrases (hCAs), paving the way for repurposing AEDs for the treatment of various diseases, including cancer. Here, the hCAs inhibitory effects of levetiracetam, a highly prescribed AED that does not bear a common zinc-binding group, were investigated and . Levetiracetam inhibited all tested hCAs, although with a specific profile compared to the reference acetazolamide, with remarkable efficacy against tumor-associated hCA IX and XII.
View Article and Find Full Text PDFComparison of Effectiveness of Brivaracetam and Levetiracetam for Prophylaxis of Early Post-Traumatic Seizures: A Prospective Comparative Interventional Study.
Asian J Neurosurg
December 2024
Department of Neurosurgery, Goa Medical College, Panaji, Goa, India.
Article Synopsis
- * This study compared the newer drug brivaracetam to levetiracetam for preventing EPTS in a clinical trial with 100 patients in Goa, India.
- * While brivaracetam showed a slightly lower incidence of EPTS and similar side effects compared to levetiracetam, the differences were not statistically significant, indicating that brivaracetam is as effective as levetiracetam in preventing EPTS.
Comparative efficacy and safety of second-line medications for status epilepticus: A network meta-analysis.
Medicine (Baltimore)
November 2024
Department of Neurology, Huaihe Hospital of Henan University, Kaifeng, China.
Background: To systematically review the efficacy and safety of second-line medications for status epilepticus (SE).
Methods: Electronic searches were conducted in PubMed, Embase, and The Cochrane Library for randomized controlled trials of second-line medications for SE from inception to January 2024. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of included studies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!